HER2-targeting small-molecule kinases like neratinib and tucatinib have demonstrated promising outcomes in the treatment of HER2-positive breast cancer, especially in patients with brain metastases (Murthy et al., 2020; Curigliano et al., 2022). Here, ERBB2 is linked to breast cancer.